Understanding ICER Thresholds Across Markets
The Incremental Cost-Effectiveness Ratio (ICER) is the single most important metric in health technology assessment. It represents the additional cost per unit of health benefit — typically measured in Quality-Adjusted Life Years (QALYs) — when comparing a new intervention to existing alternatives.
Yet despite its universal importance, the thresholds used to judge whether an ICER is "acceptable" vary dramatically from country to country.
$25K–$150K
Global ICER Range
The gap between the lowest and highest willingness-to-pay thresholds across major HTA agencies.
Why Thresholds Matter
An ICER of $60,000/QALY might earn enthusiastic approval in one market while triggering outright rejection in another. For pharmaceutical companies pursuing global launches, this variation creates a strategic puzzle: how do you price a therapy to maximize access across diverse markets?
The answer lies in understanding not just the numbers, but the institutional context behind each threshold.
The Major Markets
United Kingdom (NICE)
NICE uses an implicit threshold of £20,000–£30,000/QALY (~$25,000–$37,500), making it one of the most stringent agencies globally. However, NICE applies modifiers for end-of-life treatments, rare diseases, and therapies with significant innovation, which can effectively raise the threshold to £50,000/QALY or higher.
NICE Severity Modifier
Since January 2022, NICE applies a severity-based modifier that can weight QALYs up to 1.7x for the most severe conditions. This effectively raises the acceptable ICER to approximately £51,000/QALY for diseases with the highest absolute shortfall in health.
Canada (CADTH)
Canada's CADTH does not publish an explicit threshold, but analyses of past decisions suggest a de facto range of CAD $50,000–$100,000/QALY (~$37,000–$75,000 USD). CADTH places heavy emphasis on clinical uncertainty and real-world generalizability, meaning even therapies below the threshold can face negative recommendations if evidence quality is lacking.
Australia (PBAC)
Australia's PBAC similarly avoids a published threshold but has historically operated around AUD $45,000–$75,000/QALY (~$30,000–$50,000 USD). PBAC is known for its rigorous approach to indirect comparisons and its skepticism toward modeled endpoints without strong clinical trial backing.
Brazil (CONITEC)
Brazil's CONITEC uses a threshold tied to 3x GDP per capita (~$25,000 USD/QALY), following WHO recommendations. However, budget impact considerations heavily influence final decisions, and therapies with high total budget impact face additional scrutiny regardless of their ICER.
The GDP-Per-Capita Trap
Common Misconception
Many teams default to the WHO's 1–3x GDP per capita rule as a universal threshold. This approach is increasingly outdated and can lead to overconfident pricing assumptions. Most HTA agencies now use country-specific criteria that may be stricter or more nuanced than GDP-based estimates.
The relationship between a country's wealth and its willingness to pay for health gains is real but imprecise. High-income countries like the UK actually apply thresholds well below what GDP-based rules would suggest, while some middle-income countries are more generous in specific therapeutic areas.
Try It: ICER Threshold Calculator
Adjust the sliders below to see how your therapy's cost-effectiveness profile compares across markets.
Your ICER
$100,000/QALY
Implications for Global Pricing
Understanding threshold variation leads to several strategic insights:
-
Sequence your launches carefully. Starting with markets that have higher thresholds (or severity modifiers) can establish a reference price that supports negotiations in stricter markets.
-
Invest in local evidence. Agencies increasingly want to see data relevant to their population. A global trial may not be enough — local budget impact modeling and real-world evidence can make or break a submission.
-
Model early, model often. Running cost-effectiveness models during Phase II (not just Phase III) allows you to identify potential pricing constraints before they become dealbreakers.
-
Consider outcomes-based agreements. In markets where your ICER is borderline, risk-sharing arrangements can bridge the gap between your asking price and the agency's comfort zone.
How Quantus Models ICER Across Markets
Video placeholder
Looking Ahead
As more countries establish formal HTA processes, the landscape of thresholds will continue to evolve. The trend is toward greater transparency but also greater complexity — with modifiers, carve-outs, and multi-criteria decision frameworks adding layers to what was once a simple cost-per-QALY calculation.
The companies that will thrive are those that treat threshold analysis not as a final check, but as a strategic input from the earliest stages of drug development.